Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer

• DOI: 10.1002/gcc.20703
• Publication Date: 2009-08-13T16:57:19Z
• Authors: Gopeshwar Narayan; Luigi Scotto; Vijayalakshmi Nee...; Sherine H. Kottoor; Ada Ho Yan Wong; Shee‐Loong Loke; Mahesh Mansukhani; Bhavana Pothuri; Jason D. Wright; Andreas M. Kaufmann; Achim Schneider; Hugo Arias‐Pulido; Qian Tao; Vundavalli V. Murty
• Keywords: Protocadherin; Demethylating agent

Abstract Cervical cancer (CC) is the second most common in women. Currently, no tractable molecular‐based therapeutic targets exist for patients with invasive CC and predictive markers of risk assessment progression precancerous lesions are identified. New molecular insights into pathogenesis urgently needed. Towards this goal, we first determined copy number alterations chromosome 4 then examined role PCDH10 mapped to 4q28 as a candidate tumor suppressor gene. We identified monosomy 47% 81 studied by SNP array found that 91% 130 harboring methylation promoter region showed aberrant hypermethylation associated downregulation gene expression cell lines exposed demethylating agent resulted profound reactivated expression. also occurs at an earliest identifiable stage low‐grade squamous intraepithelial lesion. Our studies demonstrate inactivation may be critical event form potentially useful target CC. © 2009 Wiley‐Liss, Inc.